泰格醫藥(03347.HK)迴應股價急挫 稱美國政策對公司目前業務沒有影響
據報美國總統拜登將簽署行政命令,增加對美國生物技術產業製造上的協助,並減少對中國的依賴。藥明生物(02269.HK)中午收報54.4元,跌18.44%,藥明康德(02359.HK)跌14.4%至70.75元,泰格醫藥(03347.HK)亦挫14.2%至65.65元。
《證券時報》引述泰格醫藥表示,從目前公開消息來看美國的政策主要針對的是臨牀前CRO業務,對公司目前業務沒有影響,因公司未有涉足CDMO及生物醫藥業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.